Prostate Cancer News

USPSTF 2012 Screening Recommendations May Have Affected Prostate Cancer Testing

USPSTF 2012 Screening Recommendations May Have Affected Prostate Cancer Testing

The impact of USPSTF recommendations on the incidence and management of prostate cancer have not yet been fully explored.

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

The BMH online survey allows patients to enter comorbidity data at home prior to consultation.

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

The cause of death was prostate cancer among 18% vs 22% of patients receiving ADT vs ADT plus MP, respectively.

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

Patients in both treatment arms had a PFS of about 9 months.

Higher Radiation Dose May Not Improve Prostate Cancer Outcomes

Higher Radiation Dose May Not Improve Prostate Cancer Outcomes

Seven hundred and fifty-one patients were assigned to the 70.2 Gy group and 748 were assigned to the 79.2 Gy group. The median follow-up was 8.4 years.

5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer

5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer

A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.

Prostate Cancer: ADT Plus Docetaxel May Improve 12-Month Quality of Life

Prostate Cancer: ADT Plus Docetaxel May Improve 12-Month Quality of Life

While patients who received docetaxel had a significant decrease in FACT-P-reported QoL between baseline and 3 months, no difference was noted between baseline and 12 months.

Single PSA Screening Does Not Improve Prostate Cancer-Related Mortality

Single PSA Screening Does Not Improve Prostate Cancer-Related Mortality

Recommendations about population-wide PSA screening are mixed, with some studies suggesting that the potential benefits of early diagnosis are outweighed by overtreatment.

Apalutamide: First FDA-Approved Agent for Non-Metastatic Castration-Resistant Prostate Cancer

Apalutamide: First FDA-Approved Agent for Non-Metastatic Castration-Resistant Prostate Cancer

Apalutamide is also the first agent to be approved for meeting the primary endpoint of metastasis-free survival.

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes

In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer

It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

Cabozantinib May Improve Survival in mCRPC Patient Subgroup

COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.

Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer

Enzalutamide Reduces Risk of Metastasis in Castration-Resistant Prostate Cancer

Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.

Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial

Prostate Cancer: Adding Zoledronate to Androgen Suppression and Radiotherapy Not Beneficial

A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.

Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer

Comparing Daily vs Weekly Image-Guided Radiotherapy for Prostate Cancer

It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.

Prostate Cancer: Assay Leads To Increased Active Surveillance Use

Prostate Cancer: Assay Leads To Increased Active Surveillance Use

AS is recommended for men with low-risk PCa; this option can mitigate treatment-related reduction in quality of life.

Early Docetaxel Plus Androgen Deprivation Therapy Prolongs Overall Survival in Prostate Cancer

Early Docetaxel Plus Androgen Deprivation Therapy Prolongs Overall Survival in Prostate Cancer

Previous studies demonstrated that patients with metastatic hormone-sensitive prostate cancer treated with docetaxel have prolonged overall survival.

Socioeconomic Status May Affect Quality of Care, Outcomes in Prostate Cancer

Socioeconomic Status May Affect Quality of Care, Outcomes in Prostate Cancer

Researchers accessed the National Prostate Cancer Register of Sweden to evaluate the treatment strategies and outcomes for 74,643 patients with Pca.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs